{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Tsai PC"],"funding":["Kaohsiung Medical University","Taitung Mackay Memorial Hospital","Kaohsiung Medical University Hospital"],"pagination":["468-486"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11261235"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["30(3)"],"pubmed_abstract":["<h4>Background/aims</h4>Chronic hepatitis C (CHC) patients who failed antiviral therapy are at increased risk for hepatocellular carcinoma (HCC). This study assessed the potential role of metformin and statins, medications for diabetes mellitus (DM) and hyperlipidemia (HLP), in reducing HCC risk among these patients.<h4>Methods</h4>We included CHC patients from the T-COACH study who failed antiviral therapy. We tracked the onset of HCC 1.5 years post-therapy by linking to Taiwan's cancer registry data from 2003 to 2019. We accounted for death and liver transplantation as competing risks and employed Gray's cumulative incidence and Cox subdistribution hazards models to analyze HCC development.<h4>Results</h4>Out of 2,779 patients, 480 (17.3%) developed HCC post-therapy. DM patients not usin"],"journal":["Clinical and molecular hepatology"],"pubmed_title":["Metformin and statins reduce hepatocellular carcinoma risk in chronic hepatitis C patients with failed antiviral therapy."],"pmcid":["PMC11261235"],"funding_grant_id":["MOHW113-TDU-B-221-134007","TTMMH-111-06","KMU-MOST 111-2314-B-037-069-MY2","KMU-NSTC 112-2635-B-037-001-MY2","KMUH111-1R04","MOST 111-2314-B-195-009-MY2","KMUHDK(A)113002","KMUH112-2R09"],"pubmed_authors":["Kao JH","Peng CY","Tsai WL","Tung SY","T-COACH Study Group","Huang CF","Cheng PN","Chen JJ","Lai HC","Tai CM","Huang YH","Chen CY","Chung WL","Yu ML","Wang JH","Yan SL","Lo CC","Yeh ML","Cheng JS","Lee PL","Tseng KC","Lo GH","Liu CH","Lin HC","Liu CJ","Chen CJ","Tsai PC","Bair MJ","Lin CW","Chien RN","Lin CY","Chiu YC","Yang CC","Chu CH","Hsieh MH","Kuo HT","Su WW","Hung CH","Dai CY","Wang CC","Huang JF"],"additional_accession":[]},"is_claimable":false,"name":"Metformin and statins reduce hepatocellular carcinoma risk in chronic hepatitis C patients with failed antiviral therapy.","description":"<h4>Background/aims</h4>Chronic hepatitis C (CHC) patients who failed antiviral therapy are at increased risk for hepatocellular carcinoma (HCC). This study assessed the potential role of metformin and statins, medications for diabetes mellitus (DM) and hyperlipidemia (HLP), in reducing HCC risk among these patients.<h4>Methods</h4>We included CHC patients from the T-COACH study who failed antiviral therapy. We tracked the onset of HCC 1.5 years post-therapy by linking to Taiwan's cancer registry data from 2003 to 2019. We accounted for death and liver transplantation as competing risks and employed Gray's cumulative incidence and Cox subdistribution hazards models to analyze HCC development.<h4>Results</h4>Out of 2,779 patients, 480 (17.3%) developed HCC post-therapy. DM patients not usin","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Jul","modification":"2025-04-04T14:46:21.169Z","creation":"2025-04-04T14:46:21.169Z"},"accession":"S-EPMC11261235","cross_references":{"pubmed":["38637957"],"doi":["10.3350/cmh.2024.0038"]}}